Loading...
Loading...
Browse all stories on DeepNewz
VisitFDA Approves Syndax's Revuforj for Acute Leukemia, Shares Rise 4%
Nov 15, 2024, 10:53 PM
The U.S. Food and Drug Administration (FDA) has approved Revuforj (revumenib), developed by Syndax Pharmaceuticals, for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation. This approval, announced on Friday, is significant as Revuforj is the first and only menin inhibitor to treat this specific type of leukemia. The drug is approved for both adult and pediatric patients one year and older. Following the announcement, Syndax Pharmaceuticals' shares rose by 4% in after-hours trading.
View original story
Markets
No • 50%
Yes • 50%
Official announcements from the European Medicines Agency
No • 50%
Yes • 50%
Syndax Pharmaceuticals' quarterly financial reports
Yes • 50%
No • 50%
Stock market data from financial platforms such as Bloomberg or Yahoo Finance
0-5 new countries • 25%
More than 15 new countries • 25%
11-15 new countries • 25%
6-10 new countries • 25%
Official announcements from Syndax Pharmaceuticals and respective national health agencies
Revuforj holds the second largest market share • 25%
Revuforj holds less than third place in market share • 25%
Revuforj holds the largest market share • 25%
Revuforj holds the third largest market share • 25%
Market analysis reports from reputable research firms
More than 20% growth • 25%
Less than 5% growth • 25%
5% to 10% growth • 25%
10% to 20% growth • 25%
Syndax Pharmaceuticals' annual financial reports